<div id="readability-page-1"><p>Citizens Financial Group Inc. RI purchased a new position in shares of  Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor  purchased 142,193 shares of the company's stock, valued at approximately $442,000. Citizens Financial Group Inc. RI owned about 0.20% of Ventyx Biosciences at the end of the most recent reporting period.</p><ul><li>Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns</li></ul><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Hudson Bay Capital Management LP acquired a new position in  Ventyx Biosciences in the second quarter worth $34,000.  Pallas Capital Advisors LLC bought a new position in shares of  Ventyx Biosciences in the second quarter valued at about $38,000.  Engineers Gate Manager LP acquired a new position in  Ventyx Biosciences during the 2nd quarter worth about $42,000.  Jump Financial LLC bought a new stake in  Ventyx Biosciences during the 2nd quarter worth about $53,000.  Finally, Jane Street Group LLC acquired a new stake in  Ventyx Biosciences in the 1st quarter valued at about $56,000. 97.88% of the stock is owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Ventyx Biosciences</strong> alerts:</span></p></div><h2>Ventyx Biosciences Stock Performance</h2><p>Shares of NASDAQ VTYX opened at $13.86 on Friday. The company has a fifty day moving average price of $9.69 and a 200 day moving average price of $5.60. Ventyx Biosciences, Inc. has a 1-year low of $0.78 and a 1-year high of $25.00. The firm has a market cap of $989.05 million, a PE ratio of -9.24 and a beta of 1.23. </p><p>Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.13.  Equities research analysts forecast that  Ventyx Biosciences, Inc. will post -2.09 EPS for the current year. </p><h2>Analysts Set New Price Targets</h2><p>A number of equities analysts have recently issued reports on VTYX shares. Clear Str lowered shares of Ventyx Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, January 7th. Oppenheimer cut shares of Ventyx Biosciences from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research note on Thursday, January 8th. HC Wainwright downgraded Ventyx Biosciences from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $14.00 price objective for the company. in a report on Thursday, January 8th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Finally, Piper Sandler lowered shares of Ventyx Biosciences from an &#34;overweight&#34; rating to a &#34;hold&#34; rating and set a $14.00 price target for the company. in a report on Thursday, January 8th. Eight analysts have rated the stock with a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, Ventyx Biosciences currently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $14.00.</p><p><b>Check Out Our Latest Report on Ventyx Biosciences</b></p><h2>Insider Buying and Selling</h2><p>In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of the business's stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the sale, the insider directly owned 489,481 shares of the company's stock, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Raju Mohan sold 47,345 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the transaction, the chief executive officer owned 2,372,863 shares of the company's stock, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.49% of the stock is owned by company insiders. </p><h2>Ventyx Biosciences Company Profile</h2> (Free Report)<p>Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.</p><h2>See Also</h2><ul><li>Five stocks we like better than Ventyx Biosciences</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Trump just signed it</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>Virtually Unknown AI Company Solving Trillion-Dollar Problem</li><li>Do not delete, read immediately</li></ul><p><strong>Want to see what other hedge funds are holding VTYX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ventyx Biosciences Right Now?</h2><p>Before you consider Ventyx Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.</p><p>While Ventyx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VTYX

<p>Citizens Financial Group Inc. RI has acquired a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX), purchasing 142,193 shares valued at approximately $442,000 during Q3. This investment represents about 0.20% ownership in the company. Other institutional investors have also recently bought shares. Ventyx's stock opened at $13.86, with a market cap of $989.05 million. The company reported earnings of ($0.32) per share, exceeding estimates. Analysts have mixed ratings on the stock, with a consensus price target of $14.00.</p>

Citizens Financial Group Inc. RI Takes Position in Ventyx Biosciences, Inc. $VTYX